Captor Therapeutics SA () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Operating profit has grown by an annual rate -5.88% of over the last 5 years

The company has declared negative results in Dec'2024 after 3 consecutive positive quarters

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PLN 377 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-122.36%

Price to Book

11.33

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Mar 2025)

Net Profit:

-11 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

77.05%

6 Months

87.83%

1 Year

36.42%

2 Years

-35.52%

3 Years

-60.61%

4 Years

-63.72%

5 Years

0.0%

Captor Therapeutics SA for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

29.28%

EBIT Growth (5y)

-5.88%

EBIT to Interest (avg)

-57.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.57

Sales to Capital Employed (avg)

0.26

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.10

EV to EBIT

-3.63

EV to EBITDA

-4.05

EV to Capital Employed

-58.22

EV to Sales

16.26

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-88.12%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -42.22% vs 200.00% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is -13.83% vs 33.80% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.60",
          "val2": "4.50",
          "chgp": "-42.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.50",
          "val2": "-10.00",
          "chgp": "-5.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.70",
          "val2": "-9.40",
          "chgp": "-13.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,486.60%",
          "val2": "-2,472.10%",
          "chgp": "-201.45%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 19.70% vs 43.48% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 45.61% vs -96.66% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.80",
          "val2": "13.20",
          "chgp": "19.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-39.70",
          "val2": "-74.70",
          "chgp": "46.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.30",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.40",
          "val2": "-70.60",
          "chgp": "45.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,828.40%",
          "val2": "-6,069.30%",
          "chgp": "324.09%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

2.60

4.50

-42.22%

Operating Profit (PBDIT) excl Other Income

-10.50

-10.00

-5.00%

Interest

0.10

Exceptional Items

0.00

Consolidate Net Profit

-10.70

-9.40

-13.83%

Operating Profit Margin (Excl OI)

-4,486.60%

-2,472.10%

-201.45%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is -42.22% vs 200.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is -13.83% vs 33.80% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

15.80

13.20

19.70%

Operating Profit (PBDIT) excl Other Income

-39.70

-74.70

46.85%

Interest

0.40

0.30

33.33%

Exceptional Items

0.00

Consolidate Net Profit

-38.40

-70.60

45.61%

Operating Profit Margin (Excl OI)

-2,828.40%

-6,069.30%

324.09%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 19.70% vs 43.48% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 45.61% vs -96.66% in Dec 2023

All Annual Results

Company CV

About Captor Therapeutics SA

Captor Therapeutics SA

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available